Table 3 Comparison of clinical characteristics between eradication and persistence groups
Factor | Eradication group | Persistence group | p value |
|---|---|---|---|
(N = 39) | (N = 19) | ||
Follow-up days, median (range) | 64 (10–434) | 88 (23–769) | 0.129 |
Male sex | 33 (84.6) | 12 (63.2) | 0.095 |
Age, years, mean ± SD | 46.1 ± 18.4 | 63.9 ± 16.3 | 0.001 |
Year | 0.005 | ||
2020 | 9 (23.1) | 0 (0.0) | |
2021 | 16 (41.0) | 4 (21.1) | |
2022 | 14 (35.9) | 15 (78.9) | |
Identification of CRE | 0.573 | ||
On admission | 1 (2.6) | 2 (10.5) | |
On contact surveillance | 3 (7.7) | 2 (10.5) | |
On regular screening | 23 (59.0) | 9 (47.4) | |
On infection suspicion | 12 (30.8) | 6 (31.6) | |
CCI ≥ 3 points | 8 (20.5) | 11 (57.9) | 0.004 |
Burn type | 0.101 | ||
Flame | 30 (76.9) | 13 (68.4) | |
Scald | 4 (10.3) | 2 (10.5) | |
Electrical | 4 (10.3) | 0 (0.0) | |
Contact | 0 (0.0) | 2 (10.5) | |
Chemical | 1 (2.6) | 2 (10.5) | |
Inhalation injury | 14 (35.9) | 6 (31.6) | 0.745 |
TBSA burn, %, mean ± SD | 41.8 ± 16.7 | 28.8 ± 17.7 | 0.009 |
ABSI score ≥ 10 points | 9 (23.1) | 6 (31.6) | 0.533 |
Central venous catheter | 37 (94.9) | 17 (89.5) | 0.591 |
Foley catheter | 39 (100.0) | 19 (100.0) | NA |
Endotracheal intubation | 19 (48.7) | 9 (47.4) | 0.923 |
Renal replacement therapy | 1 (2.6) | 0 (0.0) | > 0.99 |
BICU days before CRE identification, median (range) | 12 (0–75) | 12 (0–57) | 0.797 |
BICU days after CRE identification, median (range) | 17 (1–169) | 30 (0–105) | 0.211 |
Positive sample for CRE | 0.147 | ||
Rectal swab only | 18 (46.2) | 5 (26.3) | |
Rectal swab and clinical sample | 21 (53.8) | 14 (73.3) | |
CP-CRE identification | 26 (66.7) | 19 (100.0) | 0.005 |
Bacteria species | 0.717 | ||
K. pneumoniae | 31 (79.5) | 17 (89.5) | |
K. aerogenes | 4 (10.3) | 2 (10.5) | |
E. coli | 1 (2.6) | 0 (0.0) | |
E. cloacae | 2 (5.1) | 0 (0.0) | |
S. marcescens | 1 (2.6) | 0 (0.0) |